Organized by KHIDI USA, Korea Biohealth R&BD Night brings together researchers, biotech and health-tech innovators, industry professionals, and other stakeholders interested in Korea–U.S. R&D collaboration and commercialization.
The evening begins with the Korea R&D Investment Strategy Seminar, where TIPA (Korea Technology and Information Promotion Agency for SMEs), KEIT (Korea Planning & Evaluation Institute of Industrial Technology), and KHIDI (Korea Health Industry Development Institute) will share their 2027 R&D investment priorities and support programs. The program also features concurrent sessions in the Havana and Santo Domingo rooms: a Grant Writing Seminar focused on U.S. and Korean funding opportunities and a Biopharma Dealmaking session exploring both sides of the negotiating table.
As the first R&BD event under KHIDI USA’s expanded R&D support activities, the evening reflects our broader effort to connect researchers and institutions, facilitate funding and R&D collaboration, and bridge promising research toward industry partnerships and business development.
See you there!
The backbone of Venture Café: come meet the community and make connections with all different kinds of innovators, including colleagues from TIPA, KEIT, and KHIDI. Along with the evening’s programming, how will you make your serendipitous moment come true?
NOTE: This block of sessions will be held entirely in Korean.
Get an inside look at where Korea’s R&D investment is headed in 2027. TIPA (Korea Technology and Information Promotion Agency for SMEs), KEIT (Korea Planning & Evaluation Institute of Industrial Technology), and KHIDI (Korea Health Industry Development Institute) will share back-to-back briefings on their 2027 R&D investment priorities and support programs.
Designed for researchers, startups, companies, and others interested in Korea-U.S. R&D opportunities, the session will highlight funding and support opportunities across different stages of research and commercialization, and offer a clearer view of how Korea’s R&D priorities are taking shape for 2027.
-
4:45 PM: TIPA (Korea Technology and Information Promotion Agency for SMEs)'s R&D Investment Priorities for 2027
Featuring Hoonbae Lee (TIPA USA). -
5:05 PM: KEIT (Korea Planning & Evaluation Institute of Industrial Technology)'s R&D Investment Priorities for 2027
Featuring Jaekeun Kim (KEIT Boston Office) -
5:25 PM: KHIDI (Korea Health Industry Development Institute)'s R&D Investment Priorities for 2027 Featuring Hyunchul Kim (KHIDI USA)
Explore both sides of the biopharma negotiating table with Ssirai Kim (Eli Lilly) sharing the buy-side perspective and Seokwon Ham (TXINNO Bioscience) presenting the sell-side view, followed by a panel discussion moderated by Sangyeul Han (CEO, Ingenia Therapeutics), featuring Ssirai Kim, Seokwon Ham, and Nikhil Madan (Harvard Business School, formerly Neurocrine Biosciences).
-
6:00 PM — Biopharma Deal Insights: The Buy-Side Perspective — Ssirai Kim (Eli Lilly)
-
6:30 PM — Biopharma Deal Insights: The Sell-Side Perspective — Seokwon Ham (TXINNO Bioscience)
-
7:00 PM — Panel Discussion: Navigating Biopharma Deals from Both Sides — Ssirai Kim (Eli Lilly), Seokwon Ham (TXINNO Bioscience), Nikhil Madan (Harvard Business School, formerly Neurocrine Biosciences), Sangyeul Han (Ingenia Therapeutics)
Presented as part of KHIDI USA's expanded support for R&D and early-stage research activities, this seminar is designed for researchers and anyone looking to strengthen their understanding of the grant application process. Four speakers will walk through different facets of grant writing, offering practical guidance and key considerations for building a competitive proposal. Yeonsik Choi (Yonsei University) will discuss the NIH K99/R00 and the transition from postdoctoral research to research independence. Bekay Ahn (ICNPM) will share strategies and key considerations for NIH R01 applications. Sunghwan Cho (GelTech Labs) then turns to the SBIR program, the federal mechanism that funds small businesses developing and commercializing new technology, walking through what actually makes a proposal stand out. Hyunchul Kim (KHIDI USA) closes out the formal talks with guidance on winning Korean R&D grants and responding to reviewer feedback, before opening the floor for a Q&A session.
-
6:00 PM — Pathways to NIH Research Independence: Strategies for K99/R00 Success — Yeonsik Choi (Yonsei University)
-
6:20 PM — Strategies for Securing NIH Funding: A Focus on R01 Grant Writing — Bekay Ahn (ICNPM)
-
6:40 PM — U.S. SBIR Grant Writing: Strategies for Developing a Competitive Proposal — Sunghwan Cho (GelTech Labs)
-
7:00 PM — Winning Korean R&D Grants: Proposal Writing and Review Response Strategies — Hyunchul Kim (KHIDI USA)
-
7:20 PM — Q&A Session — Hyunchul Kim (KHIDI USA)
Organized by KHIDI USA, Korea Biohealth R&BD Night brings together researchers, biotech and health-tech innovators, industry professionals, and other stakeholders interested in Korea–U.S. R&D collaboration and commercialization.
The evening begins with the Korea R&D Investment Strategy Seminar, where TIPA (Korea Technology and Information Promotion Agency for SMEs), KEIT (Korea Planning & Evaluation Institute of Industrial Technology), and KHIDI (Korea Health Industry Development Institute) will share their 2027 R&D investment priorities and support programs. The program also features concurrent sessions in the Havana and Santo Domingo rooms: a Grant Writing Seminar focused on U.S. and Korean funding opportunities and a Biopharma Dealmaking session exploring both sides of the negotiating table.
As the first R&BD event under KHIDI USA’s expanded R&D support activities, the evening reflects our broader effort to connect researchers and institutions, facilitate funding and R&D collaboration, and bridge promising research toward industry partnerships and business development.
See you there!
The backbone of Venture Café: come meet the community and make connections with all different kinds of innovators, including colleagues from TIPA, KEIT, and KHIDI. Along with the evening’s programming, how will you make your serendipitous moment come true?
NOTE: This block of sessions will be held entirely in Korean.
Get an inside look at where Korea’s R&D investment is headed in 2027. TIPA (Korea Technology and Information Promotion Agency for SMEs), KEIT (Korea Planning & Evaluation Institute of Industrial Technology), and KHIDI (Korea Health Industry Development Institute) will share back-to-back briefings on their 2027 R&D investment priorities and support programs.
Designed for researchers, startups, companies, and others interested in Korea-U.S. R&D opportunities, the session will highlight funding and support opportunities across different stages of research and commercialization, and offer a clearer view of how Korea’s R&D priorities are taking shape for 2027.
-
4:45 PM: TIPA (Korea Technology and Information Promotion Agency for SMEs)'s R&D Investment Priorities for 2027
Featuring Hoonbae Lee (TIPA USA). -
5:05 PM: KEIT (Korea Planning & Evaluation Institute of Industrial Technology)'s R&D Investment Priorities for 2027
Featuring Jaekeun Kim (KEIT Boston Office) -
5:25 PM: KHIDI (Korea Health Industry Development Institute)'s R&D Investment Priorities for 2027 Featuring Hyunchul Kim (KHIDI USA)
Explore both sides of the biopharma negotiating table with Ssirai Kim (Eli Lilly) sharing the buy-side perspective and Seokwon Ham (TXINNO Bioscience) presenting the sell-side view, followed by a panel discussion moderated by Sangyeul Han (CEO, Ingenia Therapeutics), featuring Ssirai Kim, Seokwon Ham, and Nikhil Madan (Harvard Business School, formerly Neurocrine Biosciences).
-
6:00 PM — Biopharma Deal Insights: The Buy-Side Perspective — Ssirai Kim (Eli Lilly)
-
6:30 PM — Biopharma Deal Insights: The Sell-Side Perspective — Seokwon Ham (TXINNO Bioscience)
-
7:00 PM — Panel Discussion: Navigating Biopharma Deals from Both Sides — Ssirai Kim (Eli Lilly), Seokwon Ham (TXINNO Bioscience), Nikhil Madan (Harvard Business School, formerly Neurocrine Biosciences), Sangyeul Han (Ingenia Therapeutics)
Presented as part of KHIDI USA's expanded support for R&D and early-stage research activities, this seminar is designed for researchers and anyone looking to strengthen their understanding of the grant application process. Four speakers will walk through different facets of grant writing, offering practical guidance and key considerations for building a competitive proposal. Yeonsik Choi (Yonsei University) will discuss the NIH K99/R00 and the transition from postdoctoral research to research independence. Bekay Ahn (ICNPM) will share strategies and key considerations for NIH R01 applications. Sunghwan Cho (GelTech Labs) then turns to the SBIR program, the federal mechanism that funds small businesses developing and commercializing new technology, walking through what actually makes a proposal stand out. Hyunchul Kim (KHIDI USA) closes out the formal talks with guidance on winning Korean R&D grants and responding to reviewer feedback, before opening the floor for a Q&A session.
-
6:00 PM — Pathways to NIH Research Independence: Strategies for K99/R00 Success — Yeonsik Choi (Yonsei University)
-
6:20 PM — Strategies for Securing NIH Funding: A Focus on R01 Grant Writing — Bekay Ahn (ICNPM)
-
6:40 PM — U.S. SBIR Grant Writing: Strategies for Developing a Competitive Proposal — Sunghwan Cho (GelTech Labs)
-
7:00 PM — Winning Korean R&D Grants: Proposal Writing and Review Response Strategies — Hyunchul Kim (KHIDI USA)
-
7:20 PM — Q&A Session — Hyunchul Kim (KHIDI USA)